Literature DB >> 20089986

Lovastatin in X-linked adrenoleukodystrophy.

Marc Engelen, Rob Ofman, Marcel G W Dijkgraaf, Michiel Hijzen, Lucinda A van der Wardt, Bjorn M van Geel, Marianne de Visser, Ronald J A Wanders, Bwee Tien Poll-The, Stephan Kemp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20089986     DOI： 10.1056/NEJMc0907735

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  16 in total

Review 1.  Adrenal insufficiency: etiology, diagnosis and treatment.

Authors:  Nicola Neary; Lynnette Nieman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

Review 2.  The Changing Face of Adrenoleukodystrophy.

Authors:  Jia Zhu; Florian Eichler; Alessandra Biffi; Christine N Duncan; David A Williams; Joseph A Majzoub
Journal:  Endocr Rev       Date:  2020-08-01       Impact factor: 19.871

Review 3.  Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Authors:  Johannes Berger; Aurora Pujol; Patrick Aubourg; Sonja Forss-Petter
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

Review 4.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

5.  Adrenoleukodystrophy: a forgotten diagnosis in children with primary Addison's disease.

Authors:  Marta Nascimento; Nádia Rodrigues; Filipa Espada; Marcelo Fonseca
Journal:  BMJ Case Rep       Date:  2012-08-21

Review 6.  Adrenoleukodystrophy - neuroendocrine pathogenesis and redefinition of natural history.

Authors:  Stephan Kemp; Irene C Huffnagel; Gabor E Linthorst; Ronald J Wanders; Marc Engelen
Journal:  Nat Rev Endocrinol       Date:  2016-06-17       Impact factor: 43.330

Review 7.  Mammalian peroxisomal ABC transporters: from endogenous substrates to pathology and clinical significance.

Authors:  Stephan Kemp; Frederica L Theodoulou; Ronald J A Wanders
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

8.  ABCD2 is a direct target of β-catenin and TCF-4: implications for X-linked adrenoleukodystrophy therapy.

Authors:  Chul-Yong Park; Han-Soo Kim; Jiho Jang; Hyunji Lee; Jae Souk Lee; Jeong-Eun Yoo; Dongjin R Lee; Dong-Wook Kim
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

9.  Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation.

Authors:  Marc Engelen; Martin J A Schackmann; Rob Ofman; Robert-Jan Sanders; Inge M E Dijkstra; Sander M Houten; Stéphane Fourcade; Aurora Pujol; Bwee Tien Poll-The; Ronald J A Wanders; Stephan Kemp
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

10.  Bezafibrate for X-linked adrenoleukodystrophy.

Authors:  Marc Engelen; Luc Tran; Rob Ofman; Josephine Brennecke; Ann B Moser; Inge M E Dijkstra; Ronald J A Wanders; Bwee Tien Poll-The; Stephan Kemp
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.